Готові списки джерел за темами / Boston. Massachusetts General Hospital. Ward 4

Добірка наукової літератури з теми "Boston. Massachusetts General Hospital. Ward 4"

Автор: Grafiati

Опубліковано: 26 липня 2024

Оновлено: 27 липня 2024

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Boston. Massachusetts General Hospital. Ward 4".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Boston. Massachusetts General Hospital. Ward 4"

Casper, Stephen. "Inexplicable patients: the case of Charles Martell and Ward 4 at the Massachusetts General Hospital." Canadian Medical Association Journal 188, no. 17-18 (August 29, 2016): 1263–64. http://dx.doi.org/10.1503/cmaj.160111.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Fridkin, Scott K., Deborah S. Yokoe, Cynthia G. Whitney, Andrew Onderdonk, and David C. Hooper. "Epidemiology of a Dominant Clonal Strain of Vancomycin-Resistant Enterococcus faecium at Separate Hospitals in Boston, Massachusetts." Journal of Clinical Microbiology 36, no. 4 (1998): 965–70. http://dx.doi.org/10.1128/jcm.36.4.965-970.1998.

Повний текст джерела

Анотація:

In 1996, the dominant (43%) strain of vancomycin-resistant enterococci (VRE; type A) at Massachusetts General Hospital was identified at Brigham and Women’s Hospital (BWH). To characterize the epidemiology of infection with type A isolates of VRE at BWH, we collected demographic and clinical data for all patients from whom VRE were isolated from a clinical specimen through September 1996. The first clinical isolates from all BWH patients from whom VRE were isolated were typed by pulsed-field gel electrophoresis ofSmaI digests of chromosomal DNA. Among patients hospitalized after the first patient at BWH infected with a type A isolate of VRE was identified, exposures were compared between patients who acquired type A isolates of VRE and those who acquired other types of VRE. Isolates from 99 patients identified to have acquired VRE were most commonly from blood (n = 27), urine (n = 19), or wounds (n = 19). Three months after the index patient arrived at BWH and at a time when ≥12 types of strains of VRE were present, type A isolates of VRE became dominant; 39 of 75 (52%) of the study cohort had acquired type A isolates of VRE. We found no association between the acquisition of type A isolates of VRE and transfer from another institution or temporal overlap by service, ward, or floor with patients known to have acquired type A isolates of VRE. By multivariate analysis, only residence in the medical intensive care unit (adjusted odds ratio [OR], 3.2; 95% confidence interval [CI], 1.4 to 107) and the receipt of two or more antibiotics per patient-day (adjusted OR, 12.2; 95% CI, 1.2 to 9.0) were associated with the acquisition of strain A. This strain of VRE, dominant at two Boston hospitals, was associated with intensity of antibiotic exposures (i.e., two or more antibiotics per patient-day). We hypothesize that this strain may have unidentified properties providing a mechanism favoring its spread and dominance over other extant isolates, and further studies are needed to define these properties.

Стилі APA, Harvard, Vancouver, ISO та ін.

Naef, Andreas P. "Claude E. Welch, A twentieth-century surgeon. My life in the Massachusetts General Hospital. Boston, Mass., Massachusetts General Hospital, 1992. XX, 392 S. Illustr. Portr. $ 24.95. ISBN 0-88135-181-4." Gesnerus 50, no. 3-4 (November 25, 1993): 303–4. http://dx.doi.org/10.1163/22977953-0500304036.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Post, Kathryn E., Lauren B. Heuer, Arif H. Kamal, Pallavi Kumar, Madeleine Elyze, Sarah Griffith, Jacqueline Han, et al. "Study protocol for a randomised trial evaluating the non-inferiority of stepped palliative care versus early integrated palliative care for patients with advanced lung cancer." BMJ Open 12, no. 2 (February 2022): e057591. http://dx.doi.org/10.1136/bmjopen-2021-057591.

Повний текст джерела

Анотація:

IntroductionIntegrating palliative care (PC) early in the illness course for patients with serious cancers improves their outcomes and is recommended by national organisations such as the American Society of Clinical Oncology. However, monthly visits with PC clinicians from the time of diagnosis can be challenging to implement due to the lack of specialty-trained PC clinicians and resources. Therefore, we developed a stepped care model to triage PC service based on patients’ needs.Methods and analysisWe are conducting a non-blinded, randomised trial to evaluate the non-inferiority of a stepped PC model compared with an early integrated PC model for improving patients’ quality of life (QOL) at 24 weeks (primary outcome). Patients assigned to early integrated PC meet with PC every 4 weeks throughout their illness. Patients assigned to stepped PC have PC visits only at clinically significant points in their illness (eg, cancer progression) unless their QOL decreases, at which time they are ‘stepped up’ and meet with PC every 4 weeks throughout the remainder of their illness. Secondary aims include assessing whether stepped PC is non-inferior to early integrated PC regarding patient-clinician communication about end of life care and length of stay on hospice as well as comparing resource utilisation. Patients are recruited from the Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Duke Cancer Center, Durham, North Carolina and University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania. The target sample size is 510 patients.Ethics and disseminationThe study is funded by the National Cancer Institute, approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board and will be reported in accordance with the Consolidated Standards of Reporting Trials statement. We will disseminate results through professional society meetings, peer-reviewed publications and presentations to patient organisations.Trial registration numberNCT03337399.

Стилі APA, Harvard, Vancouver, ISO та ін.

Miller, Julie, Annie Hsieh, Amin Nohman, David Reuss, Ilker Eyuepoglu, Daniel Cahil, Christine Jungk, and Tareq Juratli. "EPID-16. A MULTI-CENTER, PROGRESSION-FREE SURVIVAL ANALYSIS IN IDH-MUTANT GLIOMAS WITH CDKN2A DELETION: IMPLICATIONS FOR PROGNOSIS AND CLINICAL TRIAL DESIGN." Neuro-Oncology 25, Supplement_5 (November 1, 2023): v118—v119. http://dx.doi.org/10.1093/neuonc/noad179.0448.

Повний текст джерела

Анотація:

Abstract Homozygous deletion of CDKN2A is an important predictor of poor prognosis in patients with IDH-mutant gliomas. The updated 2021 WHO classification now recognizes this alteration as sufficient for the designation of an astrocytoma, IDH-mutant, WHO Grade 4, which otherwise requires histological observation of necrosis or microvascular proliferation. While overall survival patterns associated with CDKN2A deletion have been well-described, we sought to characterize progression-free survival (PFS) in this patient population. Across three institutions (Massachusetts General Hospital, Boston; University Hospital Heidelberg, Heidelberg; TU Dresden, Dresden), we identified 48 patients with IDH-mutant gliomas in which CDKN2A deletion was detected at the time of diagnosis, followed for a median of 15.2 years. The average age of the cohort is 35 years, with 60% of the patients identified as male. Most patient received immediate treatment after surgery, with 81% of the cohort undergoing radiation therapy and 73% receiving chemotherapy. Based on RANO criteria, the median progression-free survival of this patient population is 2.8 years (95% CI 1.4 – 3.3 years) and median overall survival is 4.3 years (95% CI 2.1 – 6.6 years). A positive T2/FLAIR mismatch sign or lack of contrast enhancement on MRI at the time of diagnosis are both associated with improved PFS in univariate regression analysis. For comparison, we identified a control cohort of 51 patients with astrocytoma, IDH-mutant, grade 4 without CDKN2A deletion from MGH, achieving grade 4 by histologic criteria. Demographics were similar to the CDKN2A-deleted cohort, with median age (37 years) and percentage of male patients (60%). Notably, however, PFS for the grade 4, CDKN2A-intact, IDH-mutant glioma comparison group is estimated at 5.9 years (95% CI 3.3 – 7.9 years). Overall, these data reinforce the accelerated disease course associated with deletion of CDKN2A in IDH-mutant gliomas, providing an important reference for clinical trial design.

Стилі APA, Harvard, Vancouver, ISO та ін.

Stewart, Elizabeth A., Katharine V. Jackson, Andrew J. Friedman, Mitchell S. Rein, Janis H. Fox, and Mark D. Hornstein. "The effect of baseline complex ovarian cysts on in vitro fertilization outcome**Data organization and analysis assisted by the Computerized Data Base Management and Analysis System; Supported by General Clinical Research grant number 5-MO 1-RR-02635, Brigham and Women’s Hospital, Boston, Massachusetts.††Presented in part to the Boston Fertility Society, Boston, Massachusetts, December 4, 1991." Fertility and Sterility 57, no. 6 (June 1992): 1274–78. http://dx.doi.org/10.1016/s0015-0282(16)55087-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Metzger, Monika, Amy Billett, Alison M. Friedmann, Matthew J. Krasin, Scott C. Howard, Howard J. Weinstein, Eric Larsen, et al. "Stanford V chemotherapy and involved field radiotherapy for children and adolescents with unfavorable risk Hodgkin lymphoma: Results of a multi-institutional prospective clinical trial." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 9502. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9502.

Повний текст джерела

Анотація:

9502 Background: To evaluate the efficacy of 12 weeks of Stanford V chemotherapy (prednisone, vinblastine, doxorubicine, nitrogen mustard, etoposide, vincristine, and bleomycin) without routine growth factor support plus response-adapted low-dose, involved-field radiotherapy (IFRT) in children and adolescents with unfavorable risk Hodgkin lymphoma (HL). Methods: Multi-institutional (St. Jude Children’s Research Hospital, Stanford University, Children’s Hospital Boston, Massachusetts General Hospital and Maine Children’s Hospital) clinical trial. One hundred forty-one patients with clinical stages IIB (n=43), IIIB (n=19), IVA (n=27), and IVB (n=52) HL were treated with 12 weeks of Stanford V chemotherapy and low dose IFRT between June 2002 and May 2011. Involved nodal sites in complete remission (CR, defined as > 75% shrinkage of the original tumor and PET negative) after 8 weeks of Stanford V received 15 Gy IFRT; those sites that achieved only partial response received 25.5 Gy IFRT after completion of all 12 weeks of chemotherapy. Results: With a median follow-up of 4.6 years, the 3-year overall and event-free survival (EFS) are 97% (SE=2%) and 79% (SE=4%) respectively. There was no significant difference in EFS by stage (IIB vs. IIIB vs. IV; P=0.84). Ten patients developed progessive disease and 18 relapsed, while 5 have died (1 after relapse in an accident and 4 of refractory disease). Most common toxicities were grade 3 hematologic with 234 episodes of neutropenia in 101 patients (72%) and 85 episodes of anemia in 52 patients (37%); Fever and neutropenia occurred 13 times in 12 patients (9%). Conclusions: Risk-adapted, combined-modality therapy using 12 weeks of Stanford V chemotherapy plus IFRT is well tolerated in this population with manageable acute toxicities. Overall survival is comparable to other more intense chemotherapy regimens. Future high-risk front line therapies may consider a Stanford V backbone with targeted intensification and further tailoring of radiation therapy.

Стилі APA, Harvard, Vancouver, ISO та ін.

Buitron de la Vega, Pablo, Erin M. Ashe, Ziming Xuan, Vi Gast, Tracey Saint-Phard, Julianna Brody-Fialkin, Felix Okonkwo, et al. "A Pharmacy Liaison–Patient Navigation Intervention to Reduce Inpatient and Emergency Department Utilization Among Primary Care Patients in a Medicaid Accountable Care Organization." JAMA Network Open 6, no. 1 (January 9, 2023): e2250004. http://dx.doi.org/10.1001/jamanetworkopen.2022.50004.

Повний текст джерела

Анотація:

ImportancePatients with unmet health-related social needs are at high risk for preventable health care utilization. Prior interventions to identify health-related social needs and provide navigation services with community resources have not taken place in pharmacy settings.ObjectiveTo evaluate an enhancement of pharmacy care to reduce hospital admissions and emergency department (ED) visits among primary care patients in a Medicaid accountable care organization (ACO).Design, Setting, and ParticipantsThis nonrandomized controlled trial was conducted from May 1, 2019, through March 4, 2021, with 1 year of follow-up. Study allocation was determined by odd or even medical record number. The study was performed at a general internal medicine practice at a large safety-net hospital in Boston, Massachusetts. Patients who qualified for the hospital’s pharmacy care program (aged 18-64 years and within the third to tenth percentile for health care utilization and cost among Medicaid ACO membership) who attended a visit with a primary care clinician were eligible. Of 770 eligible patients, 577 were approached, 127 declined, and 86 could not be contacted.InterventionsPatients in the control group received usual pharmacy care focused on medication adherence. Patients in the intervention group received enhanced pharmacy care with an additional focus on identification of and intervention for health-related social needs. The intervention took place for 1 year.Main Outcomes and MeasuresThe primary outcome was inpatient hospital admissions and ED visits (composite outcome) in the 12 months after enrollment during the intervention period.ResultsAmong 364 allocated patients (mean [SD] age, 50.1 [10.1] years; 216 women [59.3%]), 35 were Hispanic of any race (9.6%) and 214 were non-Hispanic Black (58.8%). All participants were included in the intention-to-treat analysis. In analyses controlling for baseline hospital admissions and ED visits the year prior to enrollment, the enhanced pharmacy care group was not associated with the odds of having any hospital admission or ED visit (adjusted odds ratio, 0.62 [95% CI, 0.23-1.62]; P = .32) among all patients and was not associated with the visit rates among those with any visit (adjusted rate ratio, 0.93 [95% CI, 0.71-1.22]; P = .62) relative to the usual pharmacy care group in the year following enrollment.Conclusions and RelevanceThe findings of this nonrandomized controlled trial suggest that inpatient and ED utilization among Medicaid ACO members at a safety-net hospital was not significantly different between groups at 1-year follow-up.Trial RegistrationClinicalTrials.gov Identifier: NCT03919084

Стилі APA, Harvard, Vancouver, ISO та ін.

Friedman, Andrew J., Margaret Daly, Juneau-Norcross, Calliope Fine, and Mitchell S. Rein. "Recurrence of myomas after myomectomy in women pretreated with leuprolide acetate depot or placebo**Supported in part by grant 7-MO1-RR02635-01 from the General Clinical Research Center, Brigham and Women’s Hospital, Boston, Massachusetts." Fertility and Sterility 58, no. 1 (July 1992): 205–8. http://dx.doi.org/10.1016/s0015-0282(16)55164-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Kathuria, Hasmeena, Divya Shankar, Vinson Cobb, Julia Newman, Katia Bulekova, Scott Werntz, and Belinda Borrelli. "Integrating Social Determinants of Health With Tobacco Treatment for Individuals With Opioid Use Disorder: Feasibility and Acceptability Study of Delivery Through Text Messaging." JMIR Formative Research 6, no. 9 (September 1, 2022): e36919. http://dx.doi.org/10.2196/36919.

Повний текст джерела

Анотація:

Background Individuals with opioid use disorder (OUD) have a high prevalence of smoking and frequently experience unmet social determinants of health (SDOH), which may be barriers to smoking cessation. Hospitalization is an opportunity to encourage smoking cessation. Unfortunately, many clinicians do not provide tobacco treatment to support the maintenance of cessation achieved during hospitalization. Interventions are required to support these high-risk individuals after hospital discharge. Objective This study aimed to test the feasibility and acceptability of a 28-day SMS text messaging program tailored to individuals with OUD, which provides smoking cessation support and addresses unmet SDOH needs. Methods From July to December 2019, we enrolled 25 individuals who were hospitalized with tobacco dependence and OUD at our large safety net hospital. The SMS text messaging program was initiated during hospitalization and continued for 28 days. Participants were enrolled in either the ready to quit within 30 days or the not ready to quit within 30 days program based on their readiness to quit. Automated SMS text messages were sent twice daily for 4 weeks. The topics included health and cost benefits of quitting, both general and opioid specific (16 messages); managing mood and stress (8 messages); motivation, coping strategies, and encouragement (18 messages); addressing medication misconceptions (5 messages); links to resources to address substance use (2 messages providing links to the Massachusetts Substance Use Helpline and Boston Medical Center resources), tobacco dependence (1 message providing a link to the Massachusetts Quitline), and unmet SDOH needs (6 messages assessing SDOH needs with links to resources if unmet SDOH needs were identified). Questionnaires and interviews were conducted at baseline and at 2 and 4 weeks after enrollment. Results The participants were 56% (14/25) female, 36% (9/25) African American, 92% (23/25) unemployed, and 96% (24/25) Medicaid insured. Approximately 84% (21/25) activated the program, and none of the participants unsubscribed. Approximately 57% (12/21) completed either the 2- or 4-week questionnaires. Program satisfaction was high (overall mean 6.7, SD 0.8, range 1-7). Many perceived that the SMS text messaging program provided social support, companionship, and motivation to stop smoking. Messages about the health benefits of quitting were well received, whereas messages on how quitting cigarettes may prevent relapse from other substances had mixed views, highlighting the importance of tailoring interventions to patient preferences. Conclusions SMS text messaging to promote smoking cessation and address SDOH needs may be an effective tool for improving quit rates and health outcomes in individuals with tobacco dependence and OUD. Our study adds to the growing body of evidence that SMS text messaging approaches are feasible and acceptable for providing tobacco treatment to all individuals who smoke, even among low-income populations who have OUD and are not ready to quit.

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Книги з теми "Boston. Massachusetts General Hospital. Ward 4"

Means, James Howard. Ward 4. Harvard University Press, 2014.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Boston. Massachusetts General Hospital. Ward 4"

Luster, Markus, and Michael Lassmann. "Radio-iodine treatment of hyperthyroidism." In Oxford Textbook of Endocrinology and Diabetes, 481–84. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199235292.003.3196.

Повний текст джерела

Анотація:

Radioactive iodine has been used successfully for almost 70 years since the first treatment took place at the Massachusetts General Hospital in Boston in 1941. However, it was not until after the Second World War that ¹³¹I became generally available for clinical applications (1). The radioactive iodine isotope is chemically identical to ‘stable’ iodine (¹²⁷I) and thus becomes a part of the intrathyroidal metabolism. Its principle of action is based on the emission of β‎-rays with a range of 0.5–2 mm in the tissue leading to high local radiation absorbed doses while sparing surrounding structures. The additional γ‎-ray component of ¹³¹I allows for scintigraphic imaging of the distribution in the gland and can also be used for pre- and post-therapeutic individual dosimetry (see below). Several therapeutic options are available for the treatment of benign thyroid disorders, namely hyperthyroidism: surgical resection (hemithyroidectomy, near-total, or total thyroidectomy), long-term antithyroid drug medication (ATD), and radio-iodine therapy (RAIT) (2, 3). These different treatment modalities are used in varying frequencies depending on geographical location, e.g. iodine supply, availability and logistics, cultural background, and patient-specific features, e.g. goitre size, presence of local symptoms, age, and hormonal status. The diversity of approaches on an international scale still remains impressive and is reflected by a great heterogeneity throughout Europe and also when compared to the USA where radio-iodine therapy is still being applied more frequently than in most European countries (4–8). Radio-iodine therapy was originally aimed at eliminating hyperthyroidism and thus leaving the patient euthyroid. Up-to-date strategies, however, established postradio-iodine induction of hypothyroidism as the treatment objective and, thus, it is included in the category of ‘cure’. This definition holds especially true for the management of Graves’ disease when long-term hypothyroidism was the rule and stabilization of euthyroidism failed in the majority of cases. In fact, the term ‘ablation’, meaning removal or destruction, has been increasingly used to characterize radio-iodine therapy and administration of larger amounts of radio-iodine have tended to make this a self-fulfilling prophecy. Although many clinicians prefer that the end result of treatment be the more easily managed hypothyroidism, others are still reluctant to give up the therapeutic ideal of euthyroidism as the preferred result of radio-iodine therapy and continue their efforts to solve the enigma of thyroid radiosensitivity.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!